Further characterization of the association of YAP1 with breast cancer according to ER expression has revealed that the role of YAP1 depends on its nuclear expression and molecular subtype, where high nuclear YAP1 expression is associated with aggressive clinical features in poor survival outcomes in the ER-negative subtype [51,52,53]. Here, ESR1 is linked to breast cancer.